A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes
Efficacy and Safety of Once-weekly Subcutaneous NNC0662-0419 in Participants With Type 2 Diabetes - a Dose-finding Study
Novo Nordisk A/S
270 participants
Apr 17, 2026
INTERVENTIONAL
Conditions
Summary
This study is being done to look at the effect and safety of different doses of NNC0662-0419 in people living with type 2 diabetes when compared to placebo or semaglutide. The purpose of this clinical study is to find out if NNC0662-0419 is effective and safe for treating people living with type 2 diabetes. Participants will get either NNC0662-0419, semaglutide or placebo. Which treatment participants get is decided by chance. NNC0662-0419 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Semaglutide is an approved medication to treat type 2 diabetes.
Eligibility
Inclusion Criteria6
- Male or female (sex at birth).
- Age 18-75 years (both inclusive) at the time of signing the informed consent.
- Glycated haemoglobin (HbA1c) of 7.0-10.0 percent (%) (53-86 millimoles per mole \[mmol/mol\]) (both inclusive) as assessed by central laboratory at screening.
- Willingness to obtain a high weight loss (greater than \[>\] 25% of weight at baseline).
- Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
- Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's Questionnaire.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
NNC0662-0419 will be administered subcutaneously.
Semaglutide will be administered subcutaneously.
Placebo will be administered subcutaneously.
Locations(63)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07415954